Alvotech (ICE:ALVO)
1,055.00
+35.00 (3.43%)
At close: Oct 7, 2025
Alvotech Revenue
Alvotech had revenue of $173.34M USD in the quarter ending June 30, 2025, a decrease of -12.79%. This brings the company's revenue in the last twelve months to $562.48M, up 82.19% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$562.48M
Revenue Growth
+82.19%
P/S Ratio
4.82
Revenue / Employee
$555.81K
Employees
1,012
Market Cap
328.05B ISK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Marel | 250.20B |
Íslandsbanki | 62.96B |
Arion banki | 61.68B |
Sildarvinnslan Hf. | 43.52B |
Brim hf. | 58.07B |
Hagar | 177.12B |
Kvika banki | 15.14B |
Festi | 147.75B |
Alvotech News
- 16 days ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 16 days ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 16 days ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire
- 16 days ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire
- 19 days ago - Alvotech Announces Marketing Approval in Japan of Three New Biosimilars - GlobeNewsWire
- 19 days ago - Alvotech Announces Marketing Approval in Japan of Three New Biosimilars - GlobeNewsWire
- 4 weeks ago - Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York - GlobeNewsWire